Consistent with findings in the MC-38 model, we observed that TLR5 agonist monotherapy inhibited tumor growth, whereas anti-PD-1 monotherapy did not show significant effects (Fig. 1C, Supplementary Fig. 2). Here, TLR5 is linked to neoplasm.